EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance

Cong Ma iD, Xuan Ji, Wenqin Huang, Senyang Guo, Lingzi Wang, Xinhong Wu, Hongmei Zheng, Jingru Wang

ACS Pharmacology & Translational Science · 12.06.2026 · 9 (6) · 1263-1284

DOI: 10.1021/acsptsci.6c00005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 13.05.2026. Verfasst von Cong Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Commission of Hubei Province, National Health Commission of the People's Republic of China, Ministry of Health of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review explores strategies to overcome the clinical limitations of Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, namely, reversible cytostasis and acquired resistance. We outline an emerging therapeutic framework in which these inhibitors induce specific vulnerabilities, shifting the treatment objective from growth suppression toward tumor clearance. Specifically, we analyze the effects of CDK4/6 inhibitors across four interconnected domains: cellular senescence, compromised DNA damage repair, metabolic reprogramming, and immune microenvironment remodeling. Building upon this framework, we summarize rational combination strategiessuch as pairing with senolytics, poly-(ADP-ribose) polymerase (PARP) inhibitors, or immune checkpoint inhibitors (ICIs)designed to exploit these induced vulnerabilities. To bridge preclinical rationale with clinical application, we discuss key translational determinants, noting that successful implementation depends on biomarker-guided patient selection and optimized dosing schedules (e.g., sequential administration) to mitigate overlapping toxicities. Collectively, the evidence suggests that rational combination strategies could repurpose CDK4/6 inhibitor therapy for more durable tumor control.

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorsDNA damage repaircellular senescencecombination therapyimmune microenvironment remodelingmetabolic reprogramming

Autor:innen und Institutionen

  • Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China.

ORCID-Profile: Cong Ma

Förderung

  • Health Commission of Hubei Province
  • National Health Commission of the People's Republic of China
  • Ministry of Health of the People's Republic of China
  • Department of Science and Technology of Hubei Province
  • Natural Science Foundation of Wuhan
  • Hubei Provincial Government
  • Hubei Cancer Hospital

Zitieren

APA

Ma, C., Ji, X., Huang, W., Guo, S., Wang, L., Wu, X., Zheng, H., & Wang, J. (2026). Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance. ACS Pharmacology & Translational Science, 9(6), 1263-1284. https://doi.org/10.1021/acsptsci.6c00005

Vancouver

Ma C, Ji X, Huang W, Guo S, Wang L, Wu X, et al. Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance. ACS Pharmacology & Translational Science. 2026;9(6):1263-1284. doi:10.1021/acsptsci.6c00005

BibTeX
@article{Ma2026,
  author = {Ma, Cong and Ji, Xuan and Huang, Wenqin and Guo, Senyang and Wang, Lingzi and Wu, Xinhong and Zheng, Hongmei and Wang, Jingru},
  title = {Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance},
  journal = {ACS Pharmacology & Translational Science},
  year = {2026},
  volume = {9},
  number = {6},
  pages = {1263--1284},
  doi = {10.1021/acsptsci.6c00005}
}
Kostenlos starten →